Skip to content
MARKETS / BALCAO / PMHS
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Polomar Health Services, Inc. PMHS

4 fiscal years on record · USD · FY2025 reported · SEC filings only
$648,231
▲ 1002.0% YoY
$-10.7M
In brief

What this company does

The Company operates Polomar Specialty Pharmacy, LLC, a State of Florida licensed retail compounding pharmacy, located in Palm Harbor, FL, pursuant to license # PH35196 (“Polomar Pharmacy”). Polomar Pharmacy is also licensed as a Special Sterile Compounding Pharmacy, permit #PH35277, which authorizes the licensed entity to dispense injectable and other sterile compounds (eye drops, infused therapeutics) upon receipt of a valid prescription. The Company is presently licensed and authorized to fulfill and deliver compounded prescribed medications in 28 states. On September 26, 2025, the Company executed a one-year non-exclusive pharmacy services agreement with CareValidate, Inc. (“CareValidate”) to fulfill GLP-1 agonist prescriptions for CareValidate’s network of on-line clinics. The Company also owns SlimRx™ (www.slimrx.com), a weight loss focused online platform that the Company plans to launch in the second quarter of 2026, that will connect patients with licensed healthcare providers to prescribe weight loss medications such as semaglutide and tirzepatide compounded with vitamin B-12 and other complementary compounded weight loss formulations (VitaSlim™ and VitaSlim Plus™), including adjunctive therapies utilizing our proprietary metformin gummy formulation. An integral part of the Company’s business model is to provide prescription fulfillment services to third party web based tele-health platforms.

Written from the business description in Polomar Health Services, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 6 May 2026. Every sentence was checked against that document before publication.

Growth
USD 648,231.00
Revenue, FY2025 · full 4-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.6 · Net income -10.7
-4M-8M2022202320242025
Compound annual growth
+165.8%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−1651 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -1627.5% · Net -1650.8%
-1000%-2000%2022202320242025
ROE
FY2025 · ROE -290.1%
-500%2022202320242025

Each USD of equity lost 290 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks

Total assetsUSD 390,043.00
EquityUSD -1.2M
CashUSD 132,150.00
Current ratio0.20×

Equity funds -313% of total assets.

The 4-year record
4 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022
Revenue $B0.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0
EBITDA $B····
Income tax $B····
Net income $B−0.0−0.0−0.0−0.0
Free cash flow $B·−0.0··
EPS, diluted $−0.39−0.05−0.020.00
Dividend / sh $····
Payout %····
ROE %−290.1−31.4−826.8−97.0
Shares out B0.030.030.030.11

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 18 reconciliationsAUDITED

Reconciled in 4 of 19 fiscal years. 77 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2022

Share this section

Download image